Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype

References

• Payton LA, Lewis JD, Byrne JA, Bright RK. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity. Cancer Immunol Immunother. 2008;57(6):1–14. doi:10.1007/s00262-007-0416-y.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Sullivan LA, Byrne JA, de Riese W, Bright RK. Memory and cellular immunity induced by a DNA vaccine encoding self-antigen TPD52 administered with soluble GM-CSF. Cancer Immunol Immunother. 2009;58(8):1337–1349. doi:10.1007/s00262-009-0659-x.
   PubMed Web of Science ®Google Scholar
• Bright JD, Schultz HN, Byrne JA, Bright RK. Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self-tumor associated antigen. OncoImmunol. 2013;7:e25049) 1–11.
   Google Scholar
• Bright RK, Bright JD, Byrne JA. Overexpressed oncogenic tumor-self antigens. Hum Vacc & Immunother. 2014;10(11):3297–3305. doi:10.4161/hv.29475.
   PubMed Web of Science ®Google Scholar
• Bright JD, Aldrich JF, Byrne JA, Bright RK. Vaccination with the prostate cancer over-expressed tumor self-protein TPD52 elicits protective tumor immunity and a potentially unique subset of CD8+ T cells. Austin J Clin Immunol. 2014;1:13.
   Google Scholar
• Mirshahidi S, Kramer VG, Whitney JB, Essono S, Lee S, Dranoff G, Anderson KS, Ruprecht RM. Overlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: Prolonged survival. Vaccine. 2009;27(12):1825–1833. doi:10.1016/j.vaccine.2009.01.089.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Payton LA, Whitford JG, Byrne JA, Smith DI, Yang L, Bright RK. Induction of tumorigenesis and metastasis by the murine orthologue of tumor protein D52. Mol Cancer Res. 2007;5(2):133–144. doi:10.1158/1541-7786.MCR-06-0245.
   PubMed Web of Science ®Google Scholar
• Shehata M, Bieche I, Boutros R, Weidenhofer J, Fanayan S, Spalding L, Zeps N, Byth K, Bright RK, Lidereau R, et al. Nonredundant functions for tumor protein D52-like proteins support specific targeting of TPD52. Clin Cancer Res. 2008;14(16):5050–5060. doi:10.1158/1078-0432.CCR-07-4994.
   PubMed Web of Science ®Google Scholar
• Balleine RL, Fejzo MS, Sathasivam P, Basset P, Clarke CL, Byrne JA. The hD52 (TPD52) gene is a candidate target gene for events resulting in increased 8q21 copy number in human breast carcinoma. Genes Chromosom Cancer. 2000;29(1):48–57. doi:10.1002/1098-2264(2000)9999:9999<:AID-GCC1005>3.0.CO;2-O.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Varambally S, Beroukhim R, Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M, Kuefer R, Fletcher JA, et al. Over expression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 2004;64(11):3814–3822. doi:10.1158/0008-5472.CAN-03-3881.
   PubMed Web of Science ®Google Scholar
• Byrne JA, Balleine RL, Fejzo MS, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Perters GB, Byth K, Karlan BY, et al. Tumor protein D52 (TPD52) is over expressed and a gene amplification target in ovarian cancer. Int J Cancer. 2005;117(6):1049–1054. doi:10.1002/ijc.21250.
   PubMed Web of Science ®Google Scholar
• Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, Gonzalez-Garcia I, Brieva JA, Dopazo J, Siebert R, Calasanz MJ, et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica. 2006;91:184–191.
   PubMed Web of Science ®Google Scholar
• Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, et al. A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354(23):2419–2430. doi:10.1056/NEJMoa055351.
   PubMed Web of Science ®Google Scholar
• Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, Kosuge T, Kanai Y, Hosoda F, Imoto I, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: Identification of genetic indicators that predict patient outcome. Cancer Sci. 2007;98(3):392–400. doi:10.1111/j.1349-7006.2007.00395.x.
   PubMed Web of Science ®Google Scholar
• Elizondo CR, Bright JD, Byrne JA, Bright RK. Analysis of CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52. Hum Vaccin Immunother. 2020;16(6):1413–1423. doi:10.1080/21645515.2019.1689746.
   PubMed Web of Science ®Google Scholar
• Bright RK, Mamula MJ. Regulation of adaptive immune responses to self-antigens in cancer and autoimmunity. Current Trends in Immunol. 2014;15:47–57.
   Google Scholar
• Kiniwa Y, Miyahara Y, Wang HY, Peng W, Peng G, Wheeler T, Thompson TC, Old LJ, Wang R. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res. 2007;13(23):6947–6958. doi:10.1158/1078-0432.CCR-07-0842.
   PubMed Web of Science ®Google Scholar
• Endharti AT, Rifa’l M, Shi Z, Fukuoka Y, Nakahara Y, Kawamoto Y, Takeda K, Isobe K, Suzuki H. Cutting edge: CD8 + CD122 + regulatory T cells produce IL-10 to suppress IFN-γ production and proliferation of CD8 + T cells. J Immunol. 2005;175(11):7093–7097. doi:10.4049/jimmunol.175.11.7093.
   PubMed Web of Science ®Google Scholar
• Saitoh O, Abiru N, Nakahara M, Nagayama Y. CD8+CD122+ T cells, a newly identified regulatory T subset, negatively regulate Graves’ hyperthyroidism in a murine model. Encocrinol. 2007;148(12):6040–6046. doi:10.1210/en.2007-0300.
   PubMed Web of Science ®Google Scholar
• Lee YH, Ishida Y, Rifa’i M, Shi Z, Isobe K, Suzuki H. Essential role of CD8+CD122+ regulatory T cells in the recovery from experimental autoimmune encephalomyelitis. J Immunol. 2008;180(2):825–832. doi:10.4049/jimmunol.180.2.825.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Shi Z, Okuno Y, Isobe K. Are CD8+CD122+ cells regulatory T cells or memory T cells? Hum Immunol. 2008;69(11):751–754. doi:10.1016/j.humimm.2008.08.285.
   PubMed Web of Science ®Google Scholar
• Wang L-X, Li Y, Yang G, Pang P-Y, Haley D, Walker EB, Urba WJ, H-M H. CD122 + CD8 + Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice. Eur J Immunol. 2010;40(5):1375–1385. doi:10.1002/eji.200839210.
   PubMed Web of Science ®Google Scholar
• Sun J, Dodd H, Moser EK, Sharma R, Braciale TJ. CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by anti-viral CTLs. Nat Immunol. 2011;12(4):327–334. doi:10.1038/ni.1996.
   PubMed Web of Science ®Google Scholar
• Rifa’i M, Shi Z, Zhang SY, Lee YH, Shiku H, Isobe K, Suzuki H. CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I–αβTCR interaction and become IL-10-producing active regulatory cells. Int Immunol. 2008;20(7):937–947. doi:10.1093/intimm/dxn052.
   PubMed Web of Science ®Google Scholar
• Lu L, Cantor H. Generation and regulation of CD8(+) regulatory T cells. Cell Mol Immunol. 2008;5(6):401–406. doi:10.1038/cmi.2008.50.
   PubMed Web of Science ®Google Scholar
• Fousteri G, Kuka M. The elusive identity of CXCR5+ CD8 T cells in viral infection and autoimmunity: Cytotoxic, regulatory, or helper cells? Mol Immunol. 2020;119:101–105. doi:10.1016/j.molimm.2020.01.007.
   PubMed Web of Science ®Google Scholar
• Toni LS, Carroll IA, Jones KL, Schwisow JA, Minobe WA, Rodriguez EM, Altman NL, Lowes BD, Gilbert EM, Buttrick PM, et al. Sequential analysis of myocardial gene expression with phenotypic change: Use of cross-platform concordance to strengthen biologic relevance. PLoS ONE. 2019;14(8):e0221519. doi:10.1371/journal.pone.0221519.
   PubMed Web of Science ®Google Scholar
• Sky Ng TH, Britton GJ, Hill EV, Verhagen J, Burton BR, Wraith DC. Regulation of adaptive immunity; the role of interleukin-10. Front Immunol. 2013;4:1–13. doi:10.3389/fimmu.2013.00001.
   PubMed Web of Science ®Google Scholar
• Burmeister Y, Lischke T, Dahler AC, Mages HW, Lam K-P, Coyle AJ, Kroczek RA, Hutloff A. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol. 2008;175:2340–2348.
   Google Scholar
• Simpson TR, Quezada SA, Allison JP. Regulation of CD4 T cell activation and effector function by inducible costimulatory (ICOS). Curr Opinion in Immunol. 2010;22(3):326–332. doi:10.1016/j.coi.2010.01.001.
   PubMed Web of Science ®Google Scholar
• Takahashi N, Matsumoto K, Saito H, Nanki T, Miyasaka N, Kobata T, Azuma M, Lee S, Mizutani S, Morio T. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J Immunol. 2009;182(9):5515–5527. doi:10.4049/jimmunol.0803256.
   PubMed Web of Science ®Google Scholar
• Redpath SA, van de Werf N, Cervera AM, MacDonald AS, Gray D, Maizels RM, Taylor MD. ICOS controls Foxp3 + regulatory T-cell expansion, maintenance and IL-10 production during helminth infection. Eur J Immunol. 2013;43(3):705–715. doi:10.1002/eji.201242794.
   PubMed Web of Science ®Google Scholar
• Barsheshet Y, Wildbaum G, Levy E, Vitenshtein A, Akinseye C, Griggs J, Lira SA, Karin N. Ccr8+foxp3+ T reg cells as master drivers of immune regulation. Pnas. 2017;114(23):6086–6091. doi:10.1073/pnas.1621280114.
   PubMed Web of Science ®Google Scholar
• Karin N. Chemokines and cancer: New immune checkpoints for cancer therapy. Current Opinion in Immunol. 2018;51:140–145. doi:10.1016/j.coi.2018.03.004.
   PubMed Web of Science ®Google Scholar
• Hoelzinger DB, Smith SE, Mirza N, Dominguez AL, Manrique SZ, Lustgarted J. Blockade of CCL1 inhibits T regulatory cell suppressive function enhancing tumor immunity without affecting T effector responses. J Immunol. 2010;184(12):6833–6842. doi:10.4049/jimmunol.0904084.
   PubMed Web of Science ®Google Scholar
• Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM, Rudensky AY. Regulatory T cells exhibit distinct features in human breast cancer. Immunity. 2016;45(5):1122–1134. doi:10.1016/j.immuni.2016.10.032.
   PubMed Web of Science ®Google Scholar
• De Simone M, Arrigoni RG, Gruarin P, Randzani V, Politano C, Politano C, Bonnal RP, Provasi E, Sarnicola M, Panzeri I, et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity. 2016;45(5):1135–1147. doi:10.1016/j.immuni.2016.10.021.
   PubMed Web of Science ®Google Scholar
• Villarreal DO, L’Huillier A, Armington S, Mottershead C, Filippova EV, Coder BD, Petit RG, Princiotta MF. Targeting CCR8 induces protective antitumor immunity and enhances vaccine-induced responses in colon cancer. Cancer Res. 2018;78(18):5340–5348. doi:10.1158/0008-5472.CAN-18-1119.
   PubMed Web of Science ®Google Scholar
• Collier JL, Weiss SA, Pauken KE, Sen DR, Sharpe AH. Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. Nature Immunol. 2021;22(7):809–819. doi:10.1038/s41590-021-00949-7.
   PubMed Web of Science ®Google Scholar